Metformin targets multiple signaling pathways in cancer

Cancer Communications

Jian Zhang¹  Evan T. Keller¹  Yanhua Yi¹  Yi Lu²  Yong Lei³  Chao-Nan Qian³  Xia Liu³  Yang Liu⁴ 

[1] Center for Translational Medicine, Guangxi Medical University, Nanning, P. R. China;Department of Urology and Pathology, School of Medicine, University of Michigan, Ann Arbor, USA;Key Laboratory of Longevity and Ageing-related Diseases, Ministry of Education, Nanning, P. R. China;School for International Education, Guangxi Medical University, Nanning, P. R. China

关键词: Metformin;    Signaling pathway;    Cancer stem cell;    Cancer;   

DOI  :  10.1186/s40880-017-0184-9

学科分类：肿瘤学

来源: Springer

【 摘 要 】

Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized.

【 授权许可】

CC BY